BACKGROUND: Cancer survival rates are important in evaluating cancer care, identifying disease patterns, and estimating the probability of death due to cancer. To date, survival rates have been calculated using other data sets with limited population coverage that may not be able to fully identify differences by treatment, geographic region, and racial or ethnic group. Data from the Centers for Disease Control and Prevention's (CDC's) National Program of Cancer Registries (NPCR) have not been used previously to calculate relative survival rates within the United States. METHODS: Data from CDC's November 2011 submission for 21 state population-based central cancer registries, representing 50 percent of the US population, were included in this analysis. This paper presents relative survival rates for diagnosis years 2000-2007 with follow-up through 2008. RESULTS: The relative survival rate for all cancers and races combined was 65.0 percent (65.3 percent for male and 64.8 percent for female patients). Black patients had a lower relative survival rate than white patients, except for lung and bronchus. For all cancers, the under 45 age groups had the highest relative survival rates, except for black males. DISCUSSION: For all cancer primary sites combined for 2000-2007, the CDC NPCR 5-year relative survival rate is comparable to that reported by the National Cancer Institute and the Canadian Cancer Registry. This analysis presents, for the first time, relative survival rates for half of the total US population and demonstrates that reliable survival rates can be calculated using CDC's NPCR data now and in the future.
BACKGROUND:Cancer survival rates are important in evaluating cancer care, identifying disease patterns, and estimating the probability of death due to cancer. To date, survival rates have been calculated using other data sets with limited population coverage that may not be able to fully identify differences by treatment, geographic region, and racial or ethnic group. Data from the Centers for Disease Control and Prevention's (CDC's) National Program of Cancer Registries (NPCR) have not been used previously to calculate relative survival rates within the United States. METHODS: Data from CDC's November 2011 submission for 21 state population-based central cancer registries, representing 50 percent of the US population, were included in this analysis. This paper presents relative survival rates for diagnosis years 2000-2007 with follow-up through 2008. RESULTS: The relative survival rate for all cancers and races combined was 65.0 percent (65.3 percent for male and 64.8 percent for female patients). Black patients had a lower relative survival rate than white patients, except for lung and bronchus. For all cancers, the under 45 age groups had the highest relative survival rates, except for black males. DISCUSSION: For all cancer primary sites combined for 2000-2007, the CDC NPCR 5-year relative survival rate is comparable to that reported by the National Cancer Institute and the Canadian Cancer Registry. This analysis presents, for the first time, relative survival rates for half of the total US population and demonstrates that reliable survival rates can be calculated using CDC's NPCR data now and in the future.
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: Kathleen K Thoburn; Robert R German; Mary Lewis; Phyllis Janie Nichols; Faruque Ahmed; Jeannette Jackson-Thompson Journal: Cancer Date: 2007-04-15 Impact factor: 6.860
Authors: Claudia Allemani; Bernard Rachet; Hannah K Weir; Lisa C Richardson; Côme Lepage; Jean Faivre; Gemma Gatta; Riccardo Capocaccia; Milena Sant; Paolo Baili; Claudio Lombardo; Tiiu Aareleid; Eva Ardanaz; Magdalena Bielska-Lasota; Susan Bolick; Rosemary Cress; Marloes Elferink; John P Fulton; Jaume Galceran; Stanislaw Gózdz; Timo Hakulinen; Maja Primic-Zakelj; Jadwiga Rachtan; Chakameh Safaei Diba; Maria-José Sánchez; Maria J Schymura; Tiefu Shen; Giovanna Tagliabue; Rosario Tumino; Marina Vercelli; Holly J Wolf; Xiao-Cheng Wu; Michel P Coleman Journal: BMJ Open Date: 2013-09-10 Impact factor: 2.692
Authors: S Jane Henley; Shayne Gallaway; Simple D Singh; Mary Elizabeth O'Neil; Natasha Buchanan Lunsford; Behnoosh Momin; Thomas B Richards Journal: J Womens Health (Larchmt) Date: 2018-10-12 Impact factor: 2.681
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167
Authors: Hilda Razzaghi; Mona Saraiya; Trevor D Thompson; S Jane Henley; Laura Viens; Reda Wilson Journal: Cancer Date: 2017-11-06 Impact factor: 6.860
Authors: Alan A Sag; Lynn A Brody; Majid Maybody; Joseph P Erinjeri; Xiaodong Wang; Thomas Wimmer; Mikhail Silk; Elena N Petre; Stephen B Solomon Journal: Clin Imaging Date: 2015-11-14 Impact factor: 2.420
Authors: David A Siegel; Lisa C Richardson; S Jane Henley; Reda J Wilson; Nicole F Dowling; Hannah K Weir; Eric W Tai; Natasha Buchanan Lunsford Journal: Cancer Date: 2020-07-29 Impact factor: 6.921
Authors: S Jane Henley; Simple D Singh; Jessica King; Reda J Wilson; Mary Elizabeth O'Neil; A Blythe Ryerson Journal: MMWR Morb Mortal Wkly Rep Date: 2017-01-27 Impact factor: 17.586
Authors: Quinn T Ostrom; Gabrielle Truitt; Haley Gittleman; Daniel J Brat; Carol Kruchko; Reda Wilson; Jill S Barnholtz-Sloan Journal: Neurooncol Pract Date: 2019-12-16
Authors: S Jane Henley; Simple D Singh; Jessica King; Reda Wilson; Mary Elizabeth O'Neil; A Blythe Ryerson Journal: MMWR Morb Mortal Wkly Rep Date: 2015-03-13 Impact factor: 17.586